Previous studies indicated that immunotherapy with a monoclonal antibody against BST2 could not only trigger antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity but also reduce tumor size and extend survival to some extent in myeloma 19. Here, BST2 is linked to neoplasm.